The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of HLA-G–targeted CAR T cells (IVS-3001) in patients with advanced HLA-G–positive solid tumors: Clinical trial in progress.
 
Samer Srour
Consulting or Advisory Role - Hansa Biopharma; Novartis
Travel, Accommodations, Expenses - Allogene Therapeutics
 
Nizar Tannir
Stock and Other Ownership Interests - Amgen; BioCryst; Johnson & Johnson/Janssen; Spdr S&P Pharmaceuticals ETF; Surface Oncology; Vanguard Health Care
Honoraria - AstraZeneca/Merck; Bristol-Myers Squibb; Eisai; Exelixis; Intellisphere; Merck Sharp & Dohme; Nektar; Oncorena
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck Sharp & Dohme; Nektar; Oncorena
Research Funding - Bristol Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst)
 
Amir Jazaeri
Stock and Other Ownership Interests - Avenge Bio; Greenfire Bio
Honoraria - Premier Research
Consulting or Advisory Role - Gerson Lehrman Group; Guidepoint Global; Iovance Biotherapeutics; Macrogenics; Sentinel Bio; Theolytics
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); GlaxoSmithKline (Inst); immatics (Inst); Imunon (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Macrogenics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Stryker
 
Matthew Campbell
Honoraria - Curio Science; Eisai; Exelixis; MJH Life Sciences; OnViv; Seagen; Targeted Oncology
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - Exelixis; SeaGen
 
Yago Nieto
Honoraria - Affimed Therapeutics
Research Funding - Affimed Therapeutics (Inst); AstraZeneca (Inst); Secura Bio (Inst)
 
Cara Haymaker
Stock and Other Ownership Interests - Briacell
Consulting or Advisory Role - Regeneron
Research Funding - Avenge Bio (Inst); BTG (Inst); Dragonfly Therapeutics (Inst); Iovance Biotherapeutics (Inst); KSQ Therapeutics (Inst); Obsidian Therapeutics (Inst); Sanofi (Inst); Yingli Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent Appl No. 62/977, 672 (Inst)
 
Ying Yuan
Consulting or Advisory Role - Abbvie; Amgen; Ascendis Pharma; Astellas Pharma; Bexion; Bristol-Myers Squibb/Celgene/Juno; Century Therapeutics; Century Therapeutics; GT Medical Technologies; Merck; NeoImmuneTech; NGM Biopharmaceuticals; Ono Pharmaceutical; Repare Therapeutics; Schrodinger; SERVIER; Umoja Biopharma; Vertex
 
Israa Salih
No Relationships to Disclose
 
Yali Yang
No Relationships to Disclose
 
Valérie Doppler
Employment - Invectys
 
Julie Garibal
Employment - Invectys
 
Marie Escande
Employment - Invectys
 
Qi Yang
Employment - Invectys Inc.
Leadership - Invectys Inc.
Stock and Other Ownership Interests - Invectys Inc.
 
Jake Kushner
Employment - Invectys
 
Jane Koo
Employment - CTMC
 
Serdar Gurses
No Relationships to Disclose
 
David Hong
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - crossbridge Bio; MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Amgen; Bayer; BeiGene; Bristol Myers Squibb Company; Janssen; Mirati Therapeutics; Sanofi and Genzyme US Companies
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Deciphera Pharmaceuticals Inc. (Inst); Genentech (Inst); Incyte (Inst); Merck Sharp & Dohme LLC (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; CLCC; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); CUE Biopharma (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); Pionyr (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - AstraZeneca; Becton Dickinson; Calibr; Cybrexa Therapeutics; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Debiopharm Group; EcoR1 Capital; eFFECTOR Therapeutics; Elevation Oncology; Exelixis; GT Aperion; Guardant Health; Harbinger Health; Incyte; Jazz Pharmaceuticals; LegoChem Biosciences; Loxo/Lilly; Menarini Group; Mersana; Molecular Templates; OnCusp Therapeutics; Protai; Ribometrix; Seagen; Tempus; Theratechnologies; Zentalis; Zymeworks
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC)
 
Aung Naing
Employment - Baylor College of Medicine and Texas Children's Hospital (I); MD Anderson Cancer Center
Honoraria - AKH Inc.; American Society of Clinical Oncology; CME Outfitters; ESMO; Korean Society of Medical Oncology (KSMO); Lynx Group; Scripps Hospital; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Abbvie; CytomX Therapeutics; Deka Biosciences; Genome & Company; Horizon Therapeutics (I); Immune-Onc Therapeutics; Janssen Biotech; Lynx Health; Merk Sharp & Dohme Corp; NGM Biopharmaceuticals; Nouscom; OncoSec; Pharming NV (I); PsiOxus Therapeutics; SERVIER; STCube Pharmaceuticals Inc.; Takeda (I)
Speakers' Bureau - Alfaisal University (I)
Research Funding - Amplimmune; Arcus Biosciences; ARMO BioSciences; Atterocor; Baxalta (I); BioNTech SE; Bristol-Myers Squibb; Calithera Biosciences; Chao Physician-Scientist Awards (I); CytomX Therapeutics; EMD Serono; Healios; Immune Deficiency Foundation (I); ImmuneOncia; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; Lilly; MedImmune; Merck; Monopteros Therapeutics; NCI; NeoImmuneTech; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; Seven and Eight Biopharmaceuticals; Sotio; Surface Oncology; The Texas Medical Center Digestive Diseases Center (I); TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences; NeoImmuneTech; NGM Biopharmaceuticals